HealthEquity

HealthEquity, Inc. provides range of solutions for managing health care accounts. The firm’s offers its solutions for employers, health plans, brokers, consultants and financial advisors. Its services include HAS, FSA, HRA, DCRA, 401(k), Commuter, COBRA and HIA. It also offers products like healthcare saving and spending platform, health savings accounts, investment advisory services, reimbursement arrangements, and healthcare incentives. The company was founded by Stephen D. Neeleman on September 18, 2002 and is headquartered in Draper, UT.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

HQY reports strong Q1 performance, faces challenges in seasonality and yield expectations

HQY's Q1 performance reflects strong growth and positive financial results, driven by increased HSA adoption and employer interest. However, the company faces challenges related to seasonality and yield expectations. To capitalize on opportunities, HQY should focus on reaching its enhanced rates target and addressing service fee pressures.

HealthEquity reports robust Q2 performance and eyes market expansion

HealthEquity's strong Q2 performance, driven by revenue and EBITDA growth, is supported by the enhanced rates product and expanded network partner footprint. While facing short-term challenges in interchange revenue and M&A environment changes, the company is well-positioned to capitalize on opportunities presented by market dynamics and regulatory discussions.

HealthEquity reports robust Q3 performance and optimistic fiscal '25 outlook

HealthEquity's Q3 performance showcased strong financial results, with raised fiscal '24 guidance and optimistic initial fiscal '25 guidance. The company is well-positioned to navigate challenges and capitalize on opportunities, particularly in expanding its market presence and enhancing customer satisfaction.

HealthEquity (HQY) posts record earnings, eyes growth through innovation

HealthEquity (HQY) delivered strong financial results, exceeding expectations and demonstrating growth across key metrics.
While facing challenges in certain business segments, the company's focus on technology, customer experience, and long-term quality positions it well for the future.
Opportunities for R&D acceleration, innovation through M&A, and expansion of product offerings present avenues for sustained growth and competitive advantage.

HealthEquity reports robust Q1 results, raises fiscal '24 guidance

HealthEquity's Q1 performance reflects strong financial growth and stability, with revenue, EBITDA, and HSA metrics showing positive trends.
The company's proactive approach to guidance revision, service fee optimization, and strategic partnerships positions it well for future success.
Challenges in managing fee pressures, COBRA impact, and M&A environment slowdown require focused strategies for sustained growth and market leadership.

HealthEquity reports robust Q2 results, eyes growth amid market shifts

HealthEquity's Q2 results reflect strong financial performance and strategic positioning for future growth.
Despite challenges in revenue consistency and market dynamics, the company's strengths in service quality and market leadership are key assets.
Opportunities in revenue growth, legislative changes, and market demand provide avenues for HealthEquity's continued success.

HealthEquity reports strong Q3 growth and bullish outlook for fiscal '25

HealthEquity's Q3 2024 earnings call highlighted impressive financial performance, strategic acquisitions, and optimistic guidance for fiscal '25, underlining the company's growth trajectory and market positioning.
While facing challenges in integrating acquisitions, maintaining competitive pricing, and managing asset maturation, HealthEquity remains focused on growth opportunities through enhanced yield products and consumer empowerment.
The company's emphasis on stability, profitability, and reinvestments, coupled with a proactive approach to engaging investors, sets the stage for continued success and market differentiation in the evolving healthcare landscape.

HealthEquity reports robust Q4 earnings, eyes growth through innovation

HealthEquity delivered strong financial results in Q4 2024, showcasing robust revenue growth and operational performance.
The company's focus on enhancing shareholder value, strategic mergers, and technology investments positions it well for future growth.
Challenges in pricing pressures and technology spend trends require careful navigation, while opportunities in HSA cash rates and digital innovations offer avenues for expansion.
Overall, HealthEquity's performance highlights resilience, strategic foresight, and a commitment to driving long-term value for stakeholders.

HealthEquity reports robust Q1 results, eyes cost savings and growth

HealthEquity's Q1 performance reflects strong growth in revenue, EBITDA, and HSA assets, underlining its market strength and operational efficiency.
The company's focus on cost savings, customer experience enhancement, and new sales growth positions it well for future success and market expansion.
While facing challenges in transitioning processes and managing costs, HealthEquity is leveraging opportunities in technology and market expansion to drive continued growth.

HealthEquity reports robust Q2 growth, unveils innovative healthcare payment options

HealthEquity's Q2 performance reflects strong growth and strategic initiatives to enhance healthcare payment options.
While facing challenges in margins and market conditions, the company's focus on innovation and team efforts bode well for future success.
Opportunities lie in leveraging HPAs, digital integration, and market expansion to drive continued growth and customer value.
Overall, HealthEquity's performance and outlook demonstrate resilience and a commitment to driving healthcare financial solutions.

HealthEquity reports robust Q3 growth amidst challenges and opportunities

HealthEquity's Q3 performance reflects strong growth and market positioning, despite challenges in gross profit margins.
The company's focus on legislative support, technology utilization, and diversified revenue streams positions it well for future expansion.
Opportunities in expanding the TAM, enhancing service delivery, and leveraging commuter offerings indicate a promising outlook for HealthEquity.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HealthEquity, Inc. engages in the provision of technology-enabled services for healthcare and spending decisions. The company was founded by Stephen D. Neeleman on September 18, 2002 and is headquartered in Draper, UT.

HealthEquity has several engines of revenue growth.

3 Drivers of HealthEquity's Long-Term Growth

HealthEquity (HQY) raises fiscal 2020 view for top and bottom line.

HealthEquity (HQY) Stock Up on Solid Fiscal 2020 Results

Shares rise after the company received some bullish praise from a Wall Street analyst.

Why HealthEquity Stock Jumped 10% Today

HealthEquity's (HQY) CEO Jon Kessler on Year-End Sales Metrics Conference Call Transcript

Nevro

Tandem Diabetes Care

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

3 Medical Product Stocks Likely to Beat This Earnings Season

HealthEquity's (HQY) fourth-quarter fiscal 2020 earnings are likely to reflect top-line growth and higher HSA member growth.

HealthEquity (HQY) to Report Q4 Earnings: What's in Store?

HealthEquity (HQY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HealthEquity (HQY) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Covanta Holding Corp

Neurocrine Biosciences

SailPoint Technologies Hlds

Zumiez

These top-ranked stocks are likely to beat on bottom line in their next releases.

Bet on Earnings Beat With 5 Top-Ranked Stocks

Solid prospects in the HSA industry consistently drive HealthEquity (HQY).

Here's Why You Should Add HealthEquity (HQY) to Portfolio Now

HealthEquity (HQY) closed the most recent trading day at $70.58, moving -1.64% from the previous trading session.

HealthEquity (HQY) Dips More Than Broader Markets: What You Should Know

Investment Desktop 2.0 allows Americans to better invest their HSA Funds Investment Desktop 2.0 allows Americans to better invest their HSA Funds

New HealthEquity Investment Desktop Maximizes Ease of Investing Health Savings Accounts

The HSA custodian delivered a strong quarterly report.

Why HealthEquity Stock Popped 17.8% in December

ERFSF vs. HQY: Which Stock Is the Better Value Option?

ERFSF or HQY: Which Is the Better Value Stock Right Now?

HealthEquity: Strong Opportunity Ahead

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider HealthEquity (HQY).

Why HealthEquity (HQY) Could Be an Impressive Growth Stock

Is  (HQY) Outperforming Other Medical Stocks This Year?

Is HealthEquity (HQY) Stock Outpacing Its Medical Peers This Year?

HealthEquity shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.
The post Stock Upgrades: HealthEquity Shows Rising Relative Strength appeared first on Investor's Business Daily.

Stock Upgrades: HealthEquity Shows Rising Relative Strength

As of late, it has definitely been a great time to be an investor HealthEquity.

Will HealthEquity Continue to Surge Higher?

Applied Materials

Goldman Sachs

The stock market saw tepid movement Friday after the US struck a phase one deal with China.

3 Stocks to Consider as Retail Spending Slows

ERFSF vs. HQY: Which Stock Should Value Investors Buy Now?

The company reported upbeat quarterly results and boosted full-year guidance.

Here's Why HealthEquity Stock Is Surging Today

HealthEquity Inc (NASDAQ: HQY) outperformed third-quarter expectations with a 47-cent bottom-line more than double analyst forecasts.

These Analysts Like HealthEquity's Post-Q3 Story

Buoyed by a solid fiscal third quarter, HealthEquity (HQY) raises its fiscal 2020 view.

Here's Why You Should Hold on to HealthEquity (HQY) for Now

HealthEquity (HQY) Earnings & Revenues Beat Estimates in Q3

HealthEquity, Inc. (HQY) CEO Jon Kessler on Q3 2020 Results - Earnings Call Transcript

News for HealthEquity Stock (HQY)